II. Indications
- Bladder Cancer or Urothelial Cancer (FGR2/3+, advanced or metastatic)
III. Mechanism
-
Fibroblast Growth Factor Receptor (FGFR)
- FGFR2 has 2 isoforms: Mesenchymal (activated by FGF2) and Epithelial (activated by FGF7 and 10)
- Mutations are associated with Craniosynostosis (Apert syndrome, crouzon syndrome)
- FGFR3 regulates chrondrocyte growth and cell differentiation
- Mutations are associated with Achondroplasia, thanatophoric dysplasia as well as neoplasms
- FGFR2 has 2 isoforms: Mesenchymal (activated by FGF2) and Epithelial (activated by FGF7 and 10)
- Cancers that may express FGFR Activity
- Urothelial carcinoma
- Hepatocellular Carcinoma
- Ovarian Cancer
- Lung Adenocarcinoma
IV. Medications
- Erdafitinib (Balversa)
V. Dosing
- See other references for disease specific dosing protocols
VI. Safety
- Avoid in Lactation
- Avoid in pregnancy (all trimesters, pregnancy category X)
- Use reliable Contraception
- Monitoring
VII. Adverse Effects
- Central Serous Retinopathy (or Retinal Detachment)
- Hyperphosphatemia
- Hand-Foot Syndrome
- Oncholysis
VIII. Drug Interactions
- Avoid with CYP2C9 Inhibitors
- Avoid with Moderate to strong CYP3A4 inhibitors and inducers